When scientific publications report their data in a manner that is incomplete or inappropriate, what might otherwise be an interesting and promising research project loses value because clinicians, patients and health policy makers are unable to use it for rational decision-making. The time and effort of the research team is wasted, and for the patients who have been enrolled into a study that is not going to deliver, there is an ethical dimension. In response to these concerns, over the last 15 years, evidence-based reporting guidelines have been devised and published, under better known acronyms such as CON-SORT (CONsolidated Standards Of Reporting Trials), STROBE (STrengthening the Reporting of OBservational studies in Epidemiology), STARD (STAndards for the Reporting of Diagnostic accuracy studies), PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses; formerly known as QUOROM) and SQUIRE (Standards for QUality Improvement Reporting Excellence). These guidelines are intended to improve quality and completeness of reporting in scientific publications. They provide useful information on how to describe research methods and findings, for example by indicating the minimum amount of methodological detail that needs to be included. The aim is to keep experimental designs transparent and to enable informed readers to understand and judge the reliability of the research presented. A recent systematic review suggested that the adoption of the CONSORT statement has been associated with an improvement in the reporting of randomised controlled trials (RCTs). 1 Not surprisingly, these reporting guidelines have been endorsed by a number of major medical journals.
The European Journal of Anaesthesiology (EJA) endorsed the CONSORT statement 10 years ago. 2 Although the Journal's Guide for Authors has specified ever since that the CONSORT guidelines should be followed when reporting RCT, it is unclear to what extent this instruction has been obeyed, so we have set out to address that question.
We screened all issues of the EJA, from January to December 2010, and classified all original articles according to their study design. Editorials, reviews or clinical guidelines were not considered. Studies concerning animal research were grouped under the same 'animal research' heading, whatever their design.
We then checked adherence of all RCT to the updated CONSORT checklist (http://www.consort-statement.org/consort-statement/overview0/). In order to better identify the specific problems related to data reporting in the EJA, item 9 of the original checklist was further split into two items, 9a (Mechanism used to implement the random allocation sequence) and 9b (Describing any step taken to conceal the sequence until interventions were assigned). Similarly, item 10 was split into three items, 10a (Who generated the random allocation sequence?), 10b (Who enrolled participants?) and 10c (Who assigned participants to interventions?). This made 39 items to be checked in total.
We computed the number and proportion of RCT reporting each item. Adherence was coded as 'yes (1)' or 'no (0)'. For item 2a (Scientific background and explanation for rationale), one point was awarded if an attempt was made to justify the research, after which the quality and validity of the original authors' justification was not further evaluated. Similarly, for item 20 (Trial limitations [bias, imprecision]), one point was attributed if limitations of the study design or biases were mentioned in the discussion, even if they were not exhaustive. Item 22 (Interpretation consistent with results, balancing benefits and harms, considering other relevant evidence) was not analysed. The maximum number of items per report was 39.
We found 130 original research articles that were published in the EJA in 2010; of these, one had been retracted, 50 (38.8%) were RCT, 26 (20.1%) were cohort studies, 21 (16.3%) concerned animals, 9 (7.0%) were surveys and 23 (17.8%) included other study designs.
Of the 50 RCT, only 24% were clearly labelled as 'randomised' in their title, 56% stated a specific study objective and 48% contained a complete and well defined prespecified primary outcome (Table 1) . Setting and location of the study, as well as the dates defining the periods of patient recruitment and follow-up were described in less than one-third of the reports. The implementation of the random sequence was described with sufficient detail in less than 20% of the trials. Finally, only six trials (12%) provided a registration number and the name of the trial registry, giving access to some aspects of their study protocol.
None of the trials reported on items 3b (Important changes to methods after commencement, with reasons), 6b (Any changes to trial outcomes after trial commenced, with reasons), or 7b (Explanation of any interim analyses and stopping guidelines). It is unclear whether these items were not reported because there were no changes to the methods or outcomes made in any of these trials, whether no interim analyses were performed, or whether this reflects incomplete reporting. Similarly, only two reports specifically described the reasons for early termination of the trial; it is uncertain whether others remained hidden.
In only 12 of the 50 RCTs (24%) could more than 50% of the 39 CONSORT items be identified (Fig. 1) . The median number of items reported was 16 (41% of all items), ranging from eight (21%) to 29 (74%). One trial each reported 29 3 and 26 4 items. Eight trials mentioned that they had followed the CONSORT statement for the establishment of a flow chart, but only one clearly stated that 'the design and the description adhere to the Consolidated Standards of Reporting clinical Trial statement'. 3 That trial reported 74% of expected items.
In 2010, the quality of data reporting of RCT in the EJA has been in the range of that previously described in a similar setting. In a study of the quality of data reporting in 108 obstetric anaesthesia RCTs, Halpern et al. 5 found
Guidelines for improved quality of data reporting 479 the median proportion of correctly described CONSORT items was 65%.
We feel there is room for improvement in the quality of data reporting of RCT in the EJA. Some items of the CONSORT checklist deserve a higher priority for improvement than others, such as identification of the study design in the title, or a clearly defined primary endpoint.
We have to be aware though that these results focus on the quality of data reporting only and do not allow any conclusion regarding the quality of the RCTs published in the EJA. As Dechartres et al. 6 highlighted in a recently published systematic review 'a study design with several biases that is well reported can receive a high-quality (of reporting) score'.
The editorial board of the EJA has introduced a number of measures to improve the quality of data reporting within the journal. A first step was to change the structure of the abstracts by adding more subheadings. We hope this will further help our authors to summarise their data. Among other measures that will follow is the creation of a new Methods, Statistics and Epidemiology section within the journal, in which we will, for instance, discuss the rationale behind the different items of the CONSORT guideline and present further reporting guidelines (for instance, PRISMA for the reporting of meta-analyses). In that section, we will also review common methodological issues related to statistics, epidemiology and study validity. We intend to remain short, practical, comprehensible and anaesthesiology oriented.
We hope these essays will assist authors to design their studies and write their manuscripts. Also, they should provide a practical guide for peer-reviewers. And last but not least, they shall engage our readers and help us to improve both the quality and attractiveness of the EJA. Percentage of the 39 items of the CONSORT checklist that were reported in 50 randomised controlled trials.
